Skip to main content

Table 2 Relationship between BCL-2 (-938C > A) polymorphism and known clinicopathological variables

From: BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility

Clinicopathological Variables

All

Genotype (%)

Adjusted a

  

AA

AC+CC

pvalue

OR

Age

     

   ≤ 40

21(18.9)

3(14.3)

18(85.7)

 

1.00

   > 40

90(81.1)

15(16.7)

75(83.3)

0.790

1.20

Pathological diagnosis

     

   Ductal

87(76.3)

14(16.1)

73(83.9)

 

1.00

   Lobular

7(6.1)

3(42.9)

4(57.1)

0.036

6.42

   Others

20(17.6)

2(10.0)

18(90.0)

0.605

0.66

Tumor size(cm)

     

   ≤ 2

50(53.2)

9(18.0)

41(82.0)

 

1.00

   > 2

44(46.8)

9(20.4)

35(79.6)

0.704

1.23

Grade

     

   I, II

59(79.7)

10(16.9)

49(83.1)

 

1.00

   III

15(20.3)

2(13.3)

13(86.7)

0.725

0.74

Positive lymph node

     

   0

34(44.7)

3(8.8)

31(91.2)

 

1.00

   1-3

25(32.9)

3(12.0)

22(88.0)

0.672

1.44

   ≥ 4

17(22.4)

7(41.2)

10(58.8)

0.014

6.95

ER

     

   Negative

28(26.9)

6(21.4)

22(78.6)

 

1.00

   Positive

76(73.1)

12(15.8)

64(84.2)

0.493

0.68

PR

     

   Negative

37(35.9)

8(21.6)

29(78.4)

 

1.00

   Positive

66(64.1)

10(15.2)

56(84.8)

0.688

0.80

Receptor status

     

   Negative

26(25.2)

6(23.1)

20(76.9)

 

1.00

   Positive

77(74.8)

12(15.6)

65(84.4)

0.115

3.06

c-erbB2

     

   Negative

73(70.2)

13(17.8)

60(82.2)

 

1.00

   Positive

31(29.8)

5(16.1)

26(83.9)

0.936

1.05

Triple-negative

     

   No

87(84.5)

14(16.1)

73(83.9)

 

1.00

   Yes

16(15.5)

4(25.0)

12(75.0)

0.444

1.67

Ki67

     

   Negative

59(58.4)

10(16.9)

49(83.1)

0.875

1.00

   Positive

42(41.6)

7(16.7)

35(83.3)

 

1.09

  1. aLogistic regression model adjusted for diagnostic age.
  2. All statistical tests were two-sided with a significance level of p ≤ 0.05.